Ryan Spencer Dynavax Technologies Corp (DVAX) insider trading activity

Ryan Spencer is CEO and Director of DYNAVAX TECHNOLOGIES CORP. Currently has a direct ownership of 260,733 shares of DVAX, which is worth approximately $2.63 Million. The most recent transaction as insider was on Feb 18, 2025, when has been sold 36,528 shares (Common Stock) at a price of $12.93 per share, resulting in proceeds of $472,307. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 261K

0% 3M change

29.7% 12M change

Total Value Held $2.63 Million

Ryan Spencer Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Feb 18 2025	SELL Payment of exercise price or tax liability	$472,307 $12.93 p/Share	36,528 Reduced 12.29%	260,733 Common Stock
Feb 18 2025	BUY Exercise of conversion of derivative security	-	55,000 Added 15.61%	297,261 Common Stock
Feb 13 2025	SELL Payment of exercise price or tax liability	$402,196 $12.69 p/Share	31,694 Reduced 11.57%	242,261 Common Stock
Feb 13 2025	BUY Exercise of conversion of derivative security	-	62,500 Added 18.6%	273,522 Common Stock
Feb 10 2025	SELL Payment of exercise price or tax liability	$147,958 $13.2 p/Share	11,209 Reduced 5.04%	211,022 Common Stock
Feb 10 2025	BUY Exercise of conversion of derivative security	-	20,833 Added 8.57%	222,231 Common Stock
Feb 15 2024	BUY Grant, award, or other acquisition	$3,798 $9.45 p/Share	402 Added 0.2%	201,030 Common Stock
Feb 12 2024	SELL Payment of exercise price or tax liability	$149,788 $12.82 p/Share	11,684 Reduced 5.5%	200,628 Common Stock
Feb 10 2024	BUY Exercise of conversion of derivative security	-	20,833 Added 8.94%	212,312 Common Stock
Feb 05 2024	SELL Payment of exercise price or tax liability	$219,079 $12.79 p/Share	17,129 Reduced 8.21%	191,479 Common Stock
Feb 04 2024	BUY Exercise of conversion of derivative security	-	29,750 Added 12.48%	208,608 Common Stock
Feb 27 2023	SELL Payment of exercise price or tax liability	$310,592 $10.36 p/Share	29,980 Reduced 14.38%	178,459 Common Stock
Feb 27 2023	BUY Exercise of conversion of derivative security	-	60,472 Added 23.85%	193,132 Common Stock
Feb 15 2023	BUY Grant, award, or other acquisition	$17,377 $9.73 p/Share	1,786 Added 1.19%	147,967 Common Stock
Aug 15 2022	BUY Grant, award, or other acquisition	$17,163 $10.29 p/Share	1,668 Added 1.13%	146,181 Common Stock
Aug 09 2022	SELL Open market or private sale	$252,463 $16.92 p/Share	14,921 Reduced 9.36%	144,513 Common Stock
Aug 08 2022	BUY Exercise of conversion of derivative security	-	29,663 Added 15.69%	159,434 Common Stock
Mar 03 2022	SELL Open market or private sale	$878,452 $10.57 p/Share	83,108 Reduced 39.04%	129,771 Common Stock
Mar 02 2022	BUY Exercise of conversion of derivative security	-	50,583 Added 20.17%	200,217 Common Stock
Feb 15 2022	BUY Grant, award, or other acquisition	$14,993 $10.29 p/Share	1,457 Added 0.89%	162,296 Common Stock
Feb 10 2022	BUY Exercise of conversion of derivative security	-	89,250 Added 35.69%	160,839 Common Stock
Aug 13 2021	BUY Grant, award, or other acquisition	$6,675 $3.39 p/Share	1,969 Added 2.68%	71,589 Common Stock
Feb 22 2021	SELL Payment of exercise price or tax liability	$103,594 $9.6 p/Share	10,791 Reduced 13.42%	69,620 Common Stock
Feb 22 2021	BUY Exercise of conversion of derivative security	-	20,833 Added 20.58%	80,411 Common Stock
Feb 22 2021	BUY Grant, award, or other acquisition	$5,149 $3.39 p/Share	1,519 Added 2.49%	59,578 Common Stock

Also insider at

CDTX

Cidara Therapeutics, Inc. Healthcare

Director

Ryan Spencer

CEO and Director

Emeryville, CA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells DVAX shares.

Notify only if

Value

Insider Trading

Get notified when an Dynavax Technologies Corp insider buys or sells DVAX shares.

Notify only if

Operation

Value

Type

News

Receive news related to DYNAVAX TECHNOLOGIES CORP

Track Activities on DVAX

Account